Invitrogen

FAH Polyclonal Antibody

Advanced Verification

This Antibody was verified by Knockdown to ensure that the antibody binds to the antigen stated.

3 Published Figures

2 References

View all (11) FAH antibodies

Datasheet

Protocols

Questions & Answers

Tech Support

Datasheet

Protocols

Questions & Answers

Tech Support

Product Image Gallery

FAH Antibody in Immunohistochemistry (Paraffin) (IHC (P)) — Immunohistochemistry analysis of FAH was performed on fah-/- (left) and wildtype (right) mouse liver paraffin sections. To expose target proteins, antigen retrieval was performed by microwaving tissues for 8-15 minutes in 10mM sodium citrate buffer (pH 6.0). Following antigen retrieval, endogenous peroxidases were blocked with 3% hydrogen peroxide-methanol for 15 min at room temperature. Tissue slides were washed with deionized water and PBS, and then blocked in 3% BSA-PBS for 30 min at room temperature. Tissues were probed with a FAH polyclonal antibody (Product # PA5-42049) diluted 1:400 in 3% BSA-PBS overnight at 4°C in a humidified chamber. Tissues were washed extensively in PBST and detection was performed using an HRP-conjugated secondary antibody followed by colorimetric detection using a DAB kit. Tissues were counterstained with hematoxylin and dehydrated with ethanol and xylene to prep for mounting. Images were taken at 20X magnification. Data courtesy of Antibody Data Exchange Program.

FAH Antibody in Immunohistochemistry (IHC) — Immunohistochemistry analysis of human liver (top) and mouse KO liver tissue (bottom) using an anti-Fumarylacetoacetase polyclonal antibody (Product # PA5-42049).

FAH Antibody in Western Blot (WB) — Western blot analysis of human liver cells using an anti-Fumarylacetoacetase polyclonal antibody (Product # PA5-42049).

FAH Antibody — Antibody specificity was demonstrated by comparing wildtype and FAH deficient mouse liver. FAH signal is detected only in the wildtype mouse liver (right panel) in IHC using Anti - FAH polyclonal Antibody (Product # PA5-42049). {KD}

Product Details

PA5-42049

Applications	Tested Dilution	Publications
Western Blot (WB)	0.2-1 µg/mL	View 1 publication 1 publication
Immunohistochemistry (IHC)	1:400	-
Immunohistochemistry (Paraffin) (IHC (P))	1:400	View 1 publication 1 publication

Product Specifications
Species Reactivity	Human, Mouse
Published species	Pig
Host/Isotype	Rabbit / IgG
Class	Polyclonal
Type	Antibody
Immunogen	Synthetic peptide directed towards the N-terminal of human FAH View antigen
Conjugate	Unconjugated
Form	Liquid
Concentration	0.5 mg/mL
Purification	Affinity Chromatography
Storage buffer	PBS with 2% sucrose
Contains	0.09% sodium azide
Storage conditions	-20° C, Avoid Freeze/Thaw Cycles
RRID	AB_2609348

Product Specific Information

Peptide sequence: SFIPVAEDSD FPIHNLPYGV FSTRGDPRPR IGVAIGDQIL DLSIIKHLFT

Sequence homology: Cow: 93%; Dog: 86%; Guinea Pig: 86%; Horse: 86%; Human: 100%; Mouse: 93%; Pig: 93%; Rat: 93%

Target Information

This gene encodes the last enzyme in the tyrosine catabolism pathway. FAH deficiency is associated with Type 1 hereditary tyrosinemia (HT).

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.

Product References

Genetically blocking HPD via CRISPR-Cas9 protects against lethal liver injury in a pig model of tyrosinemia type I.

Molecular therapy. Methods & clinical development

Gu P,Yang Q,Chen B,Bie YN,Liu W,Tian Y,Luo H,Xu T,Liang C,Ye X,Liu Y,Tang X,Gu W

PA5-42049 was used in Western Blot to report an improved single-step method to establish a biallelic (FAH-/- ) mutant porcine model using CRISPR-Cas9 and cytoplasmic microinjection.

Fri Jun 11 00:00:00 EDT 2021

Genetically blocking HPD via CRISPR-Cas9 protects against lethal liver injury in a pig model of tyrosinemia type I.

Molecular therapy. Methods & clinical development

Gu P,Yang Q,Chen B,Bie YN,Liu W,Tian Y,Luo H,Xu T,Liang C,Ye X,Liu Y,Tang X,Gu W

PA5-42049 was used in Western Blot to report an improved single-step method to establish a biallelic (FAH-/- ) mutant porcine model using CRISPR-Cas9 and cytoplasmic microinjection.

Fri Jun 11 00:00:00 EDT 2021

Genetically blocking HPD via CRISPR-Cas9 protects against lethal liver injury in a pig model of tyrosinemia type I.

Molecular therapy. Methods & clinical development

Gu P,Yang Q,Chen B,Bie YN,Liu W,Tian Y,Luo H,Xu T,Liang C,Ye X,Liu Y,Tang X,Gu W

PA5-42049 was used in Western Blot to report an improved single-step method to establish a biallelic (FAH-/- ) mutant porcine model using CRISPR-Cas9 and cytoplasmic microinjection.